CURX

Curanex Pharmaceuticals Inc Common Stock

There isn't enough reported data to score CURX yet.

CURX Fundamentals

MetricStatus
Unavailable
Weak
Unavailable
Unavailable

CURX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.

CURX PE Valuation

CURX has no meaningful PE right now: it lost money over the past year.

CURX Forward outlook

There aren't enough analyst estimates for CURX to show an outlook.

CURX Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $5.67 on Nov 12.

There is not enough scenario data to assess CURX's risk to reward.

CURX Earnings Per Share

Q3 2024: $-0.17Q4 2024: $-0.26Q1 2025: $-0.30Q2 2025: $-0.27Q3 2025: $-1.00Q4 2025: $-3.30Q1 2026: $-5.40Q2 2026: $-7.80
Q3 2024: $-0.17Q4 2024: $-0.26Q1 2025: $-0.30Q2 2025: $-0.27Q3 2025: $-1.00Q4 2025: $-3.30Q1 2026: $-5.40Q2 2026: $-7.80
QuarterTTM EPSYoY
Q2 2026-$7.80-$7.53
Q1 2026-$5.40-$5.10
Q4 2025-$3.30-$3.04
Q3 2025-$1.00-$0.83

CURX lost $7.80 per share over the past year, and its loss has widened in each of the last four quarters.

CURX Quarterly Revenue

Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --
Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --

CURX Free Cash Flow

Q4 2023: --Q1 2024: --Q2 2024: −$236,328Q3 2024: --Q4 2024: --Q1 2025: −$149,948Q2 2025: --Q3 2025: −$9MQ4 2025: −$857,404Q1 2026: −$954,560Q2 2026: −$1M
Q4 2023: --Q1 2024: --Q2 2024: −$236,328Q3 2024: --Q4 2024: --Q1 2025: −$149,948Q2 2025: --Q3 2025: −$9MQ4 2025: −$857,404Q1 2026: −$954,560Q2 2026: −$1M
QuarterFree cash flowYoY
Q1 2026-$954.6K-$804.6K

CURX Total Shares

Q4 2023: 1MQ1 2024: 1MQ2 2024: 1MQ3 2024: 1MQ4 2024: 1MQ1 2025: 1MQ2 2025: 1MQ3 2025: 1MQ4 2025: 1MQ1 2026: 1MQ2 2026: 1M
Q4 2023: 1MQ1 2024: 1MQ2 2024: 1MQ3 2024: 1MQ4 2024: 1MQ1 2025: 1MQ2 2025: 1MQ3 2025: 1MQ4 2025: 1MQ1 2026: 1MQ2 2026: 1M
PeriodChange %Net change
Quarterly+0.1%+1K shares
1 year+18%+218K shares

CURX has 1M diluted shares, up 18% from a year ago.

CURX Net Leverage

CURX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

CURX Weekly Momentum

MetricValueStatus
RSI62.0Neutral
Stochastic64.1Neutral

CURX's weekly RSI is 62 (neutral) and its Stochastic is 64 (neutral).

CURX PE vs Healthcare Sector

CURX has no meaningful PE right now: it lost money over the past year.

CURX Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$5.1311% above
20 week MA$4.7120% above
50 week MA$6.3310% below

CURX has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 10% below its 50-week average.

CURX Yearly ROI

YearStart priceEnd priceROI
2025$112.0$7.27-94%
2026 YTD$7.27$5.67-22%

CURX has finished every year since 2025 lower, and it's down 22% so far in 2026.

Give your agent the market.

Get API key